Business
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”)Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regionsAdvanced the Cu
About this update from Johnson & Johnson
[{"type":"image","alt":"Nanobiotix S.A.","displaySize":"","headline":null,"caption":"Nanobiotix S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/w.WG45QhRIjOjkLYfarG8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998","width":300,"height":100}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 million","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Progress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”)","length":209,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regions","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Advanced the Curadigm Nanoprimer program with updated plans for internal pipeline development and external collaborations","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical updates from ongoing or completed JNJ-1900 (NBTXR3) Phase 1 studies sponsored by Nanobiotix or MD Anderson in melanoma, lung cancer amenable to re-irradiation, pancreatic cancer, and esophageal cancer expected in 2026","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"€20.4 million in cash and cash equivalents as of September 30, 2025","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":903,"olType":false},{"type":"text","content":"PARIS and CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today reported an operational update and financial results for the third quarter of 2025 along with an outlook for clinical updates from studies sponsored by Nanobiot...